Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat

Behav Brain Res. 2010 Nov 12;213(1):66-72. doi: 10.1016/j.bbr.2010.04.034. Epub 2010 Apr 29.

Abstract

L-dopa induced dyskinesia is a complication of long-term L-dopa administration in patients with Parkinson's disease. This study uses the rodent model of dyskinesia to determine whether prior dopamine agonist treatment causes long-term changes that influence the development of L-dopa mediated behaviours. Rats with unilateral 6-OHDA lesions were injected with dopamine agonists (ropinirole, piribedil bromocriptine, all 1mg/kg) or saline (0.9%) daily for 21 days. Following a 1-week drug free interval L-dopa was administered for 15 days (10mg/kg with benserazide 15 mg/kg in saline s.c.). Rotational behaviour and abnormal involuntary movements (AIMs) were recorded at regular intervals. All dopamine agonists induced a contralateral rotational response on day 1, which increased in response to repeated administration but did not by themselves induce overt dyskinesias. On day 1 of L-dopa administration animals pre-treated with piribedil and ropinirole produced a more severe rotational response. In the saline pre-treated group, AIMs developed with repeated L-dopa administration, which was reflected in the increased expression of PPE-B mRNA. There was a trend for the same pattern in the dopamine agonist treated groups but this was non-significant. Therefore, while locomotor sensitivity is altered by the pre-treatment with dopamine agonists, there appears to be no increased risk of developing AIMs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiparkinson Agents / adverse effects
  • Antiparkinson Agents / pharmacology*
  • Bromocriptine / administration & dosage
  • Bromocriptine / pharmacology
  • Corpus Striatum / drug effects
  • Corpus Striatum / metabolism
  • Dopamine Agonists / administration & dosage
  • Dopamine Agonists / pharmacology*
  • Dyskinesia, Drug-Induced / complications
  • Dyskinesia, Drug-Induced / drug therapy*
  • Enkephalins / metabolism
  • Female
  • Indoles / administration & dosage
  • Indoles / pharmacology
  • Levodopa / adverse effects
  • Levodopa / pharmacology*
  • Oxidopamine
  • Parkinsonian Disorders / chemically induced
  • Parkinsonian Disorders / complications
  • Parkinsonian Disorders / drug therapy*
  • Piribedil / administration & dosage
  • Piribedil / pharmacology
  • Protein Precursors / metabolism
  • RNA, Messenger / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Rotation
  • Time Factors

Substances

  • Antiparkinson Agents
  • Dopamine Agonists
  • Enkephalins
  • Indoles
  • Protein Precursors
  • RNA, Messenger
  • ropinirole
  • Bromocriptine
  • Levodopa
  • Oxidopamine
  • preproenkephalin
  • Piribedil